AZD1208

AZD1208 is a highly selective and potent pan-PIM kinase inhibitor. Displayed efficacy in models of acute myeloid leukemia, prostate cancer, and triple-negative breast cancer. Combination treatment of AZD1208 and imatinib eliminated chronic myelogenous leukemia stem cells in cell culture and a patient-derived mouse xenograft model. It improved immunotherapeutic antitumor T-cell response and disrupted the myeloid cell-mediated immunosuppressive tumor microenvironment increasing T-cell-mediated antitumor immunity.